Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trialEileen M. Boyle, Xavier Leleu, Marie‐Odile Petillon et al.|British Journal of Haematology|2019Cited by 23
SFBC guidelines on critical care testingMichel Vaubourdolle, Agnès Mailloux, Hélène Caillon et al.|Annales de biologie clinique|2016Cited by 4
Critical care testing: SFBC recommendations in 2018Michel Vaubourdolle, Marie-Hélène Tournoys, Françoise Barbé et al.|Annales de biologie clinique|2018Cited by 4